Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 12, 2011, Pages 3775-3784

  Arlt, Wiebke ^a   Biehl, Michael ^b   Taylor, Angela E ^a   Hahner, Stefanie ^c   Libé, Rossella ^d   Hughes, Beverly A ^a   Schneider, Petra ^a   Smith, David J ^a   Stiekema, Han ^b   Krone, Nils ^a   Porfiri, Emilio ^a   Opocher, Giuseppe ^e   Bertherat, Jerôme ^d   Mantero, Franco ^e,f   Allolio, Bruno ^c   Terzolo, Massimo ^g   Nightingale, Peter ^h   Shackleton, Cedric H L ^a   Bertagna, Xavier ^d   Fassnacht, Martin ^c   Stewart, Paul M ^a   more..

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d RenéDescartes University ^*  (France)

^e VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

^g UNIVERSITY OF TURIN   (Italy)

^h WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; STEROID;

ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL TUMOR; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HORMONE DETERMINATION; HUMAN; MACHINE LEARNING; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METABOLOMICS; METASTASIS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STEROID EXCRETION; STEROID URINE LEVEL; STEROIDOGENESIS; TUMOR DIFFERENTIATION; URINALYSIS;

ADRENAL CORTEX HORMONES; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL ADENOMA; ADRENOCORTICAL CARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; METABOLOMICS; MIDDLE AGED;

EID: 83155177174     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1565     Document Type: Article

References (37)

1. Grumbach MM, Biller BM, Braunstein GD, Campbell KK, Carney JA, Godley PA, Harris EL, Lee JK, Oertel YC, Posner MC, Schlechte JA, Wieand HS 2003 Management of the clinically inapparent adrenal mass ("incidentaloma") . Ann Intern Med 138:424-429 (Pubitemid 36262654)
2. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR 2004 The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 25:309-340 (Pubitemid 38528713)
3. Barzon L, Sonino N, Fallo F, Palu G, Boscaro M 2003 Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 149:273-285 (Pubitemid 37304697)
4. Terzolo M, Reimondo G, Angeli A 2009 Definition of an optimal strategy to evaluate and follow-up adrenal incidentalomas: time for further research. Eur J Endocrinol 161:529-532
5. Young Jr WF 2007 Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 356:601-610 (Pubitemid 46220820)
6. Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S 2009 Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant: time for a rethink? Eur J Endocrinol 161:513-527
7. Nieman LK 2010 Approach to the patient with an adrenal incidentaloma. J Clin Endocrinol Metab 95:4106-4113
8. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Alì A, Giovagnetti M, Opocher G, Angeli A 2000 A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 85:637-644
9. Reincke M, Nieke J, Krestin GP, Saeger W, Allolio B, Winkelmann W 1992 Preclinical Cushing's syndrome in adrenal "incidentalomas": comparison with adrenal Cushing's syndrome. J Clin Endocrinol Metab 75:826-832
10. Terzolo M, Bovio S, Reimondo G, Pia A, Osella G, Borretta G, Angeli A 2005 Subclinical Cushing's syndrome in adrenal incidentalomas. Endocrinol Metab Clin North Am 34:423-439, x (Pubitemid 40602730)
11. Stewart PM 2010 Is subclinical Cushing's syndrome an entity or a statistical fallout from diagnostic testing? Consensus surrounding the diagnosis is required before optimal treatment can be defined. J Clin Endocrinol Metab 95:2618-2620
12. Allolio B, Fassnacht M 2006 Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 91:2027-2037
13. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B German Adrenocortical Carcinoma Registry Group; European Network for the Study of Adrenal Tumors 2009 Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 115:243-250
14. Weiss LM, Medeiros LJ, Vickery Jr AL 1989 Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 13:202-206 (Pubitemid 19081702)
15. Lau SK, Weiss LM 2009 The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Hum Pathol 40:757-768
16. de Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, Houlgatte R, Bertherat J, Bertagna X, Plouin PF, Baudin E, Berger F, Gicquel C, Chabre O, Feige JJ 2005 Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 90:1819-1829 (Pubitemid 40464057)
17. de Reyniès A, Assié G, Rickman DS, Tissier F, Groussin L, René-Corail F, Dousset B, Bertagna X, Clauser E, Bertherat J 2009 Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 27:1108-1115
18. Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bauersfeld J, Sanders D, Thomas DG, Doherty G, Hammer G 2009 Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res 15:668-676
19. Hamrahian AH, Ioachimescu AG, Remer EM, Motta-Ramirez G, Bogabathina H, Levin HS, Reddy S, Gill IS, Siperstein A, Bravo EL 2005 Clinical utility of noncontrast computed tomography attenuation value (Hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab 90:871-877 (Pubitemid 40279211)
20. Boland GW, Dwamena BA, Jagtiani Sangwaiya M, Goehler AG, Blake MA, Hahn PF, Scott JA, Kalra MK 2011 Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. Radiology 259:117-126
21. Minowada S, Kinoshita K, Hara M, Isurugi K, Uchikawa T, Niijima T 1985 Measurement of urinary steroid profile in patients with adrenal tumor as a screening method for carcinoma. Endocrinol Jpn 32:29-37
22. Doerr HG, Sippell WG, Drop SL, Bidlingmaier F, Knorr D 1987 Evidence of 11β-hydroxylase deficiency in childhood adrenocortical tumors. The plasma corticosterone/11-deoxycorticosterone ratio as a possible marker for malignancy. Cancer 60:1625-1629 (Pubitemid 17141018)
23. Grondal S, Eriksson B, Hagenas L, Werner S, Curstedt T 1990 Steroid profile in urine: a useful tool in the diagnosis and follow up of adrenocortical carcinoma. Acta Endocrinol (Copenh) 122:656-663 (Pubitemid 20183387)
24. Małunowicz EM, Ginalska-Malinowska M, Romer TE, Ruszczyñska-Wolska A, Dura M 1995 Heterogeneity of urinary steroid profiles in children with adrenocortical tumors. Horm Res 44:182-188
25. Shackleton CH, Marcos J 2011 GC/MS steroid profiling: diagnosis of disorders affecting steroid synthesis and metabolism. In: Gross M, Caprioli R, eds. The encyclopedia of mass spectrometry. Vol 8. Amsterdam: Elsevier; 789-813
26. Krone N, Hughes BA, Lavery GG, Stewart PM, Arlt W, Shackleton CH 2010 Gas chromatography/mass spectrometry (GC/MS) remains a pre-eminent discovery tool in clinical steroid investigations even in the era of fast liquid chromatography tandem mass spectrometry (LC/MS/MS). J Steroid Biochem Mol Biol 121:496-504
27. Kohonen T 1997 Self-organizing maps. Berlin: Springer
28. Schneider P, Biehl M, Hammer B 2009 Adaptive relevance matrices in learning vector quantization. Neural Comput 21:3532-3561
29. McCullagh P, Nelder JA 1989 Generalized linear models. London: Chapman and Hall
30. Ilias I, Sahdev A, Reznek RH, Grossman AB, Pacak K 2007 The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer 14:587-599 (Pubitemid 350074049)
31. 18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. J Clin Endocrinol Metab 94:1713-1722
32. 18F-fluorodeoxyglucose positron emission tomography/computed tomography with computed tomography and shift magnetic resonance imaging. J Int Med Res 38:633-644
33. Blake MA, Cronin CG, Boland GW 2010 Adrenal imaging. AJR Am J Roentgenol 194:1450-1460
34. Korobkin M, Brodeur FJ, Francis IR, Quint LE, Dunnick NR, Londy F 1998 CT time-attenuation washout curves of adrenal adenomas and nonadenomas. AJR Am J Roentgenol 170:747-752 (Pubitemid 28106677)
35. Soldin SJ, Soldin OP 2009 Steroid hormone analysis by tandem mass spectrometry. Clin Chem 55:1061-1066
36. Janzen N, Sander S, Terhardt M, Peter M, Sander J 2008 Fast and direct quantification of adrenal steroids by tandem mass spectrometry in serum and dried blood spots. J Chromatogr B Analyt Technol Biomed Life Sci 861:117-122 (Pubitemid 350298062)
37. Rossi C, Calton L, Hammond G, Brown HA, Wallace AM, Sacchetta P, Morris M 2010 Serum steroid profiling for congenital adrenal hyperplasia using liquid chromatography-tandem mass spectrometry. Clin Chim Acta 411:222-228